Jazz Pharmaceuticals, Inc. and Johnson & Johnson Services, Inc. are dominating the U.S. Psychedelic Drugs Market in 2019

U.S. Psychedelic Drugs Market is expected to grow at a substantial CAGR of 16.3% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report at https://www.databridgemarketresearch.com/reports/us-psychedelic-drugs-market

U.S. psychedelic drugs market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in the U.S. psychedelic drugs market are introducing strong range of product portfolio. This has also helped the company to maximize the sales with enhanced product portfolio.

Jazz Pharmaceuticals, Inc. is the dominating player in the U.S. psychedelic drugs market and accounts the highest market share in 2019, which is followed by Johnson & Johnson Services, Inc., Celon Pharma SA, COMPASS, usonainstitute.org, Develco pharma schweiz ag , Doughlas pharmaceuticals limited , NeuroRX, Inc, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals, LLC., AVADEL PHARMACEUTICALS, PLC among others.

Jazz Pharmaceuticals, Inc.:

Jazz Pharmaceuticals, Inc. headquartered in Dublin, Ireland was founded in 2003.

The company is engaged in transforming biopharmaceutical discoveries into novel life-changing medicines to treat rare or complex diseases.  The company is providing product under medicines (our medicines, drug safety, medical information), research (pipeline, clinical trials, expanded access, independent scientific research) categories. The company is continuously engaged in manufacturing and developments of psychedelic drugs.  

• In September 2019, Jazz Pharmaceuticals, Inc. has published optimistic data sets from JZP-258’s Phase 3 study for the treatment of excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The Phase 3 clinical study data sets will help company to upsurge its market presence as the product is a unique formulation and has 92% less sodium as compared to Xyrem (sodium oxybate).

It has global networks through direct sales representatives and distributors in the North America, Europe through its subsidiaries Jazz Pharmaceuticals Ireland Limited (Ireland), Jazz Financing I Designated Activity Company (Ireland), Jazz Capital Limited (Ireland), Jazz Pharmaceuticals, Inc. (U.S.), Celator Pharmaceuticals, Inc.(U.S.) among others.

Johnson & Johnson Services, Inc.:

Johnson & Johnson Services, Inc. headquartered in New Jersey, U.S.  was founded in 1886. The company is engaged in the research and development, manufacturing and sale of a wide range of products in the health care field. The company is providing products under consumer health products, medical devices, and pharmaceutical products categories. The company is operating in pharmaceutical, medical devices, and consumer segments. The market focus products lie under pharmaceutical segments. The company is continuously engaged in manufacturing and developments of psychedelic drugs.

• In March 2019, Johnson & Johnson Services, Inc. has received the U.S. Food and drug Administration (FDA) authorization for SPRAVATOTM (esketamine) nasal spray CIII antidepressant for treatment-of resistant depression. The U.S. Food and Drug Administration (FDA) authorization will help company to lead the market as the product is first new mechanism of action for treatment of major depressive disorder in decades.

 The company has wide global presence across the globe such as Europe, Asia-Pacific, Middle East & Africa, and Americas through its subsidiaries Johnson & Johnson Vision Care, Inc. (U.S.), Neutrogena (U.S.), DePuy Synthes (U.S.), Ethicon USA, LLC (U.S.) and Janssen Global Services, LLC (Belgium) among others.